Seeking Alpha

Soligenix gets orphan designation for SGX94

  • Soligenix (SNGX.OB) scores an orphan designation for the innate defense regulator SGX94 in patients with acute radiation syndrome.
  • In clinical models, the drug minimized damage to the skin and gastrointestinal tract, and "enabled clearance of infection as a result of damage to the hematopoietic system." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|